Literature DB >> 11525305

Cancer of the esophagogastric junction.

H J Stein1, M Feith, J R Siewert.   

Abstract

In the Western world, there has been an alarming rise in the incidence and prevalence of adenocarcinoma arising at the esophagogastric junction during recent decades. Epidemiological, clinical and pathological data support a sub-classification of adenocarcinomas arising in the vicinity of the esophagogastric junction (AEG) into adenocarcinoma of the distal esophagus (Type I), true carcinoma of the cardia (Type II) and subcardial carcinoma (Type III). While most, if not all, adenocarcinomas of the distal esophagus arise from areas with specialized intestinal metaplasia, which develop as a consequence of chronic gastroesophageal reflux, the etiology and pathogenesis of true carcinoma of the gastric cardia and subcardial gastric cancer is not clear at present. Although a subgroup of true carcinomas of the gastric cardia may also develop within short segments of intestinal metaplasia at the esophagogastric junction, a causal relation between these tumors and gastroesophageal reflux has been difficult to establish. Irrespective of the etiology, a complete removal of the primary tumor and its lymphatic drainage has to be the primary goal of any surgical approach to adenocarcinoma of the esophagogastric junction. Our experience in the management of more than 1000 such patients during the past 18 years suggests that an individualized therapeutic strategy oriented by tumor type and stage results in survival rates superior to those reported with a more indiscriminate approach. This individualized strategy prescribes a transmediastinal esophagectomy with lymphadenectomy in the lower posterior mediastinum and along the celiac axis for Type I tumors, extended total gastrectomy with transhiatal resection of the distal esophagus and D2 lymphadenectomy for Type II and Type III tumors, a limited resection of the esophagogastric junction and distal esophagus with interposition of a pedicled jejunal segment for uT1N0 tumors, and neoadjuvant chemotherapy followed by resection for uT3/T4 tumors. Extensive preoperative staging is essential to allow correct selection of the appropriate therapeutic strategy using this tailored approach.

Entities:  

Mesh:

Year:  2000        PMID: 11525305     DOI: 10.1016/s0960-7404(00)00021-9

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  43 in total

1.  Scintigraphic evaluation of jejunal interposition after distal esophageal resection for early Barrett's carcinoma.

Authors:  Albrecht W Stier; Marcus Feith; Christiane Weigel; Marcus Schwaiger; Claus D Heidecke; Hubert J Stein
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

Review 2.  Multimodality therapy for gastroesophageal cancers.

Authors:  Kenneth K Wang
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 3.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

4.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

5.  Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques.

Authors:  Bryan J Dicken; Kathryn Graham; Stewart M Hamilton; Sam Andrews; Raymond Lai; Jennifer Listgarten; Gian S Jhangri; L Duncan Saunders; Sambasivarao Damaraju; Carol Cass
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

6.  Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas.

Authors:  Wei-Han Zhang; Xin-Zu Chen; Kai Liu; Kumar Anil; Kun Yang; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

7.  Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.

Authors:  Akiko Kawano; Takako Eguchi Nakajima; Ichiro Oda; Nobukazu Hokamura; Satoru Iwasa; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Hirofumi Fujii; Yasuhiro Shimada
Journal:  Gastric Cancer       Date:  2013-02-24       Impact factor: 7.370

8.  The esophagogastric junctional adenocarcinoma an increasing disease.

Authors:  Monica Pastina; Cecilia Menna; Claudio Andreetti; Mohsen Ibrahim
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

9.  Submucosal tunneling endoscopic resection for submucosal tumors of the esophagogastric junction originating from the muscularis propria layer: a feasibility study (with videos).

Authors:  Xiao-Yun Wang; Mei-Dong Xu; Li-Qing Yao; Ping-Hong Zhou; Douglas Pleskow; Quan-Lin Li; Yi-Qun Zhang; Wei-Feng Chen; Yun-Shi Zhong
Journal:  Surg Endosc       Date:  2014-02-11       Impact factor: 4.584

10.  Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.

Authors:  Jan Johansson; Pauline Djerf; Stefan Oberg; Thomas Zilling; Christer Staël von Holstein; Folke Johnsson; Bruno Walther
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.